Literature DB >> 11408417

Decreased monocarboxylate transporter 1 in rat soleus and EDL muscles exposed to clenbuterol.

T Kitaura1, N Tsunekawa, H Hatta.   

Abstract

We hypothesized that a shift in muscle fiber type induced by clenbuterol would change monocarboxylate transporter 1 (MCT1) content and activity of lactate dehydrogenase (LDH) and isoform pattern and shift myosin heavy chain (MHC) pattern in soleus (Sol) and extensor digitorum longus (EDL) of male rats. In the clenbuterol-administered rats (2.0 mg x kg(-1) x day(-1) subcutaneously for 4 wk), the ratio of muscle weight to body weight increased in the Sol (P < 0.05) and the EDL (P < 0.01). Clenbuterol induced the appearance of fast MHC(2D) and decreased slow MHC(1) in Sol (13%) but had no effect on EDL. The MHC pattern of Sol changed from slow to fast type. Clenbuterol increased LDH-specific activity (P < 0.01) and the ratio of the muscle-type isozyme of LDH to the heart type (P < 0.05) in Sol. The LDH total activity of the EDL muscle was also increased (P < 0.05). Furthermore, MCT1 content significantly (P < 0.05) decreased in both Sol and EDL (27 and 52%, respectively). This study suggests that clenbuterol might mediate the shift of MHC from slow to fast type and the changes in the regulation of lactate metabolism. Novel to this study is the observation that clenbuterol decreases MCT1 content in the hindlimb muscles and that the decrease in MCT1 is not muscle-type specific. It may suggest that the genetic expressions of individual factors involving slow-type MHC, heart-type isozyme of LDH, and MCT1 are associated with one another but are regulated independently.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11408417     DOI: 10.1152/jappl.2001.91.1.85

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  7 in total

1.  Molecular impact of clenbuterol and isometric strength training on rat EDL muscles.

Authors:  Rémi Mounier; Hélian Cavalié; Gérard Lac; Eric Clottes
Journal:  Pflugers Arch       Date:  2006-11-09       Impact factor: 3.657

2.  Effects of dexamethasone on the expression of beta(1)-, beta (2)- and beta (3)-adrenoceptor mRNAs in skeletal and left ventricle muscles in rats.

Authors:  Fuuun Kawano; Jun Tanihata; Shogo Sato; Sachiko Nomura; Akira Shiraishi; Kaoru Tachiyashiki; Kazuhiko Imaizumi
Journal:  J Physiol Sci       Date:  2009-07-08       Impact factor: 2.781

3.  Adaptive effects of the beta2-agonist clenbuterol on expression of beta2-adrenoceptor mRNA in rat fast-twitch fiber-rich muscles.

Authors:  Shogo Sato; Sachiko Nomura; Fuuun Kawano; Jun Tanihata; Kaoru Tachiyashiki; Kazuhiko Imaizumi
Journal:  J Physiol Sci       Date:  2009-12-23       Impact factor: 2.781

Review 4.  Muscle plasticity and β₂-adrenergic receptors: adaptive responses of β₂-adrenergic receptor expression to muscle hypertrophy and atrophy.

Authors:  Shogo Sato; Ken Shirato; Kaoru Tachiyashiki; Kazuhiko Imaizumi
Journal:  J Biomed Biotechnol       Date:  2011-11-15

5.  Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) and serine biosynthetic pathway genes are co-ordinately increased during anabolic agent-induced skeletal muscle growth.

Authors:  D M Brown; H Williams; K J P Ryan; T L Wilson; Z C T R Daniel; M H D Mareko; R D Emes; D W Harris; S Jones; J A D Wattis; I L Dryden; T C Hodgman; J M Brameld; T Parr
Journal:  Sci Rep       Date:  2016-06-28       Impact factor: 4.379

6.  Effects of clenbuterol administration on mitochondrial morphology and its regulatory proteins in rat skeletal muscle.

Authors:  Yu Kitaoka; Daiki Watanabe; Yudai Nonaka; Kazuyoshi Yagishita; Yutaka Kano; Daisuke Hoshino
Journal:  Physiol Rep       Date:  2019-10

7.  Intracellular β2-adrenergic receptor signaling specificity in mouse skeletal muscle in response to single-dose β2-agonist clenbuterol treatment and acute exercise.

Authors:  Shogo Sato; Ken Shirato; Ryosuke Mitsuhashi; Daisuke Inoue; Takako Kizaki; Hideki Ohno; Kaoru Tachiyashiki; Kazuhiko Imaizumi
Journal:  J Physiol Sci       Date:  2013-03-13       Impact factor: 2.781

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.